Syo Takuya 荘拓也

… Alternative Names

Sho Takuya 荘拓也

Less

Researcher Number	50581104
Other IDs
Affiliation (Current)	2025: 北海道大学, 大学病院, 助教
Affiliation (based on the past Project Information) *help	2021 – 2024: 北海道大学, 大学病院, 助教
Review Section/Research Field	Principal Investigator Basic Section 53010:Gastroenterology-related
Keywords	Principal Investigator 肝癌幹細胞 / HCC / CXCL9 / FGFR4 / 免疫寛容 / cancer stem like cells / 腫瘍免疫 / 肝がん / FGF / 免疫チェックポイント阻害剤 / 癌幹細胞 / 肝癌

肝癌のFGFR4-CXCL9 axis を介した免疫チェックポイント阻害剤耐性化機構の解析Principal Investigator
- Principal Investigator
  
  荘拓也
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Hokkaido University
Elucidation of Maintenance and Immune Tolerance Mechanisms in hepatocellular carcinoma Stem Cells and Optimization of Therapeutic ApproachesPrincipal Investigator
- Principal Investigator
  
  Sho Takuya
- Project Period (FY)
  2021 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Hokkaido University

All 2023 2022 2021

All Journal Article

[Journal Article] Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan2023
- Author(s)
  Sasaki Takashi、Kawagishi Naoki、et.al.,
- Journal Title
  
  Hepatology Research
  
  Volume: 53 Issue: 10 Pages: 960-967
- DOI
  10.1111/hepr.13936
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K14998, KAKENHI-PROJECT-22K08023, KAKENHI-PROJECT-22K08046, KAKENHI-PROJECT-21K07953
[Journal Article] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?2023
- Author(s)
  Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, et al.
- Journal Title
  
  Targeted Oncology
  
  Volume: 18 Issue: 2 Pages: 221-233
- DOI
  10.1007/s11523-023-00953-x
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-21K07950, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-21K07184
[Journal Article] Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index2023
- Author(s)
  PERSANO MARA、RIMINI MARGHERITA、Sho Takuya et al.,
- Journal Title
  
  Anticancer Research
  
  Volume: 43 Issue: 4 Pages: 1599-1610
- DOI
  10.21873/anticanres.16310
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07953
[Journal Article] Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma2023
- Author(s)
  Ohara Masatsugu、Suda Goki、Kohya Risako、Sasaki Takashi、Yoda Tomoka、Yoshida Sonoe、Fu Qingjie、Yang Zijian、Hosoda Shunichi、Maehara Osamu、Ohnishi Shunsuke、Tokuchi Yoshimasa、Kitagataya Takashi、Kawagishi Naoki、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Ogawa Koji、Sakamoto Naoya
- Journal Title
  
  Frontiers in Nutrition
  
  Volume: 10 Pages: 1-10
- DOI
  10.3389/fnut.2023.1272728
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K16008, KAKENHI-PROJECT-23K14998, KAKENHI-PROJECT-23K14999, KAKENHI-PROJECT-22K08023, KAKENHI-PROJECT-22K08046, KAKENHI-PROJECT-21K07953
[Journal Article] Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight2023
- Author(s)
  Tokuchi Yoshimasa、Sho Takuya et al.,
- Journal Title
  
  Hepatology Research
  
  Volume: in press Issue: 7 Pages: 595-606
- DOI
  10.1111/hepr.13899
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-22K08046, KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-20K17008, KAKENHI-PROJECT-23K24311
[Journal Article] Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma2023
- Author(s)
  Kohya Risako、Suda Goki、Kawagishi Naoki、et.al.,
- Journal Title
  
  Cancers
  
  Volume: 15 Issue: 12 Pages: 3257-3257
- DOI
  10.3390/cancers15123257
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K14998, KAKENHI-PROJECT-23K14999, KAKENHI-PROJECT-22K08023, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-23K24311
[Journal Article] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients2023
- Author(s)
  Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, et al.
- Journal Title
  
  Journal of Cancer Research and Clinical Oncology
  
  Volume: ー Issue: 10 Pages: 7565-7577
- DOI
  10.1007/s00432-023-04678-2
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-21K07950, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-22K08046, KAKENHI-PROJECT-21K07184, KAKENHI-PROJECT-21K08008
[Journal Article] Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis2023
- Author(s)
  Nakai Masato、Morikawa Kenichi、Sasaki Takashi、Kohya Risako、Yoshida Sonoe、Hosoda Shunichi、Kubo Akinori、Tokuchi Yoshimasa、Kitagataya Takashi、Yamada Ren、Ohara Masatsugu、Sho Takuya、Suda Goki、Ogawa Koji、Sakamoto Naoya
- Journal Title
  
  Journal of Gastroenterology
  
  Volume: 58 Issue: 7 Pages: 656-667
- DOI
  10.1007/s00535-023-01993-w
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07953
[Journal Article] Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis2022
- Author(s)
  Yoshida Sonoe、Suda Goki、et al.,
- Journal Title
  
  Hepatology Research
  
  Volume: in press Issue: 7 Pages: 603-613
- DOI
  10.1111/hepr.13765
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-22K16008, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-20K17008
[Journal Article] Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave1502022
- Author(s)
  Sho Takuya et al.,
- Journal Title
  
  Cancers
  
  Volume: 14 Issue: 16 Pages: 3938-3938
- DOI
  10.3390/cancers14163938
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008
[Journal Article] Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI2021
- Author(s)
  Kubo Akinori、Suda Goki、Kimura Megumi、Maehara Osamu、Tokuchi Yoshimasa、Kitagataya Takashi、Ohara Masatsugu、Yamada Ren、Shigesawa Taku、Suzuki Kazuharu、Kawagishi Naoki、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Morikawa Kenichi、Ogawa Koji、Ohnishi Shunsuke、Sakamoto Naoya
- Journal Title
  
  Cancers
  
  Volume: 13 Issue: 14 Pages: 3633-3633
- DOI
  10.3390/cancers13143633
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008, KAKENHI-PROJECT-20K17039
[Journal Article] Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy2021
- Author(s)
  Sho Takuya、Morikawa Kenichi、Kubo Akinori、Tokuchi Yoshimasa、Kitagataya Takashi、Yamada Ren、Shigesawa Taku、Kimura Mugumi、Nakai Masato、Suda Goki、Natsuizaka Mitsuteru、Ogawa Koji、Sakamoto Naoya
- Journal Title
  
  World Journal of Gastrointestinal Oncology
  
  Volume: 13 Issue: 12 Pages: 2076-2087
- DOI
  10.4251/wjgo.v13.i12.2076
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953
[Journal Article] Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass2021
- Author(s)
  Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
- Journal Title
  
  J Viral Hepat.
  
  Volume: in press Issue: 5 Pages: 755-763
- DOI
  10.1111/jvh.13484
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008
[Journal Article] Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C2021
- Author(s)
  Kawagishi Naoki、Suda Goki、Kimura Megumi、Maehara Osamu、Yamada Ren、Tokuchi Yoshimasa、Kubo Akinori、Kitagataya Takashi、Shigesawa Taku、Suzuki Kazuharu、Ohara Masatsugu、Nakai Masato、Sho Takuya、Natsuizaka Mitsuteru、Morikawa Kenichi、Ogawa Koji、Kudo Yusuke、Nishida Mutsumi、Sakamoto Naoya
- Journal Title
  
  Scientific Reports
  
  Volume: 11 Issue: 1 Pages: 9207-9207
- DOI
  10.1038/s41598-021-88632-7
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K21592, KAKENHI-PROJECT-19H03630, KAKENHI-PROJECT-20K08298, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008
[Journal Article] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria2021
- Author(s)
  Sho Takuya、Suda Goki、et al.,
- Journal Title
  
  Hepatology Research
  
  Volume: 51 Issue: 9 Pages: 979-989
- DOI
  10.1111/hepr.13693
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17008
[Journal Article] FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma2021
- Author(s)
  Maehara Osamu、Suda Goki、Natsuizaka Mitsuteru、Shigesawa Taku、Kanbe Gouki、Kimura Megumi、Sugiyama Masaya、Mizokami Masashi、Nakai Masato、Sho Takuya、Morikawa Kenichi、Ogawa Koji、Ohashi Shinya、Kagawa Shingo、Kinugasa Hideaki、Naganuma Seiji、Okubo Naoto、Ohnishi Shunsuke、Takeda Hiroshi、Sakamoto Naoya
- Journal Title
  
  Cancer Biology & Therapy
  
  Volume: 22 Issue: 5-6 Pages: 372-380
- DOI
  10.1080/15384047.2021.1939638
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08458, KAKENHI-PROJECT-20K21592, KAKENHI-PROJECT-19H03630, KAKENHI-PROJECT-20K08371, KAKENHI-PROJECT-21K07953, KAKENHI-PROJECT-20K17039

1. 坂本直哉 (10334418)

# of Collaborated Projects: 2 results

# of Collaborated Products: 6 results
2. 須田剛生 (20447460)

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
3. KUDO Masatoshi

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
4. 川岸直樹

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
5. 西田直生志

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
6. 森川賢一

# of Collaborated Projects: 0 results

# of Collaborated Products: 4 results
7. 大原正嗣

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
8. 小川浩司

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Syo Takuya 荘 拓也

Sho Takuya 荘 拓也

Research Projects

Research Products

Co-Researchers

肝癌のFGFR4-CXCL9 axis を介した免疫チェックポイント阻害剤耐性化機構の解析Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of Maintenance and Immune Tolerance Mechanisms in hepatocellular carcinoma Stem Cells and Optimization of Therapeutic ApproachesPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave1502022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass2021

Author(s)

Journal Title

Syo Takuya 荘拓也

Sho Takuya 荘拓也